Literature DB >> 11126150

Bladder-sphincter biofeedback as treatment of detrusor instability in women who failed to respond to oxybutynin.

A C Wang1.   

Abstract

BACKGROUND: This study was designed to determine the efficacy of bladder-sphincter-biofeedback as a secondary treatment for those women with detrusor instability who failed to respond to oxybutynin chloride.
METHODS: In a prospective non-randomized trial, 31 of 70 women with detrusor instability were assigned to either the study bladder-sphincter-biofeedback training group (n = 16) or to the control pelvic floor exercise group (n = 15) after they had failed to respond to oxybutynin chloride.
RESULTS: Thirty (43%) of the 70 women were cured by oxybutynin chloride, and 9 (13%) withdrew due to various side effects. A comparison of cure rates between biofeedback training and pelvic floor exercise groups demonstrated that there were significant differences in objective changes: detrusor pressure (68.75% vs. 0%, p < 0.001), compliance (75.0% vs. 6.67%, p < 0.001), and resting maximal urethral closure pressure (43.75% vs. 6.67%, p < 0.037). Neither the cure rate nor improvement rate of subjective changes (urgency, and frequency and episodes of urge incontinence), significantly differed.
CONCLUSION: Oxybutynin chloride was not well tolerated while bladder-sphincter-biofeedback was well accepted. As a secondary treatment, it appears better than pelvic floor exercise alone and may be the choice of non-surgical treatment in those women who failed to respond to oxybutynin chloride for detrusor instability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126150

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  3 in total

Review 1.  Biofeedback for the treatment of female pelvic floor muscle dysfunction: a systematic review and meta-analysis.

Authors:  Fátima Faní Fitz; Ana Paula Magalhães Resende; Liliana Stüpp; Marair Gracio Ferreira Sartori; Manoel João Batista Castello Girão; Rodrigo Aquino Castro
Journal:  Int Urogynecol J       Date:  2012-03-17       Impact factor: 2.894

2.  Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.

Authors:  Julian F Guest; Dele Abegunde; Francis J Ruiz
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 3.  Conservative therapy for overactive bladder: pelvic floor exercises.

Authors:  Christina Kwon; Peter K Sand
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.